Most importantly, given the potential benefits of insulin in the management of AD, concurrent use of insulin and rivastigmine as a single drug delivery system, perhaps as a prodrug or as an adjunct treatment, could be considered since the inhibitory action of rivastigmine on AChE is preserved even at considerable concentrations of insulin in vitro. The gene discussed is INS; the disease is Alzheimer disease.